Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates

Journal of Medicinal Chemistry

Volumn 54, Issue 10, 2011, Pages 3606-3623

  Zhao, Robert Y ^a   Wilhelm, Sharon D ^a   Audette, Charlene ^a   Jones, Gregory ^a   Leece, Barbara A ^a   Lazar, Alexandru C ^a   Goldmacher, Victor S ^a   Singh, Rajeeva ^a   Kovtun, Yelena ^a   Widdison, Wayne C ^a   Lambert, John M ^a   Chari, Ravi V J ^a  

^a IMMUNOGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 SULFO N SUCCINIMIDYL 4 (2 PYRIDYLDITHIO)BUTANOATE MAYTANSINOID 4 CONJUGATE; ANTIBODY CONJUGATE; MACROGOL; MACROGOL MALEIMIDE MAYTANSINOID CONJUGATE; MAYTANSINOID; N HYDROXYSUCCINIMIDE; N HYDROXYSUCCINIMIDE MAYTANSINOID 1 CONJUGATE; SUCCINIMIDYL 4 (N MALEIMIDOMETHYL)CYCLOHEXANE 1 CARBOXYLATE MAYTANSINOID 4 CONJUGATE; SULFONATED IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DISULFIDE BOND; DRUG CONJUGATION; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN TISSUE; HYDROPHILICITY; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; TUMOR VOLUME;

ANIMALS; ANTIBODIES; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMMUNOCONJUGATES; MAYTANSINE; MICE; MODELS, CHEMICAL; NEOPLASM TRANSPLANTATION; POLYETHYLENE GLYCOLS; SUCCINIMIDES; SULFONES;

EID: 79957730092     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm2002958     Document Type: Article

References (42)

1. Verstappen, C. C.; Heimans, J. J.; Hoekman, K.; Postma, T. J. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management Drugs 2003, 63, 1549-1563 (Pubitemid 36976138)
2. Kohler, G.; Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity Nature 1975, 256, 495-497
3. Penault-Llorca, F.; Etessami, A.; Bourhis, J. Principal therapeutic uses of monoclonal antibodies in oncology Cancer Radiother. 2002, 6 (Suppl. 1) 24s-28s (Pubitemid 36034400)
4. Wu, A. M.; Senter, P. D. Arming antibodies: prospects and challenges for immunoconjugates Nat. Biotechnol. 2005, 23, 1137-1146 (Pubitemid 41486395)
5. Blattler, W. A.; Lambert, J. M.; Goldmacher, V. S. Realizing the full potential of immunotoxins Cancer Cells 1989, 1, 50-55 (Pubitemid 20185099)
6. Chari, R. V. Targeted cancer therapy: conferring specificity to cytotoxic drugs Acc. Chem. Res. 2008, 41, 98-107
7. Chari, R. V. Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy Adv. Drug Delivery Rev. 1998, 31, 89-104 (Pubitemid 28191877)
8. Senter, P. D. Potent antibody drug conjugates for cancer therapy Curr. Opin. Chem. Biol. 2009, 13, 235-244
9. Widdison, W. C.; Wilhelm, S. D.; Cavanagh, E. E.; Whiteman, K. R.; Leece, B. A.; Kovtun, Y.; Goldmacher, V. S.; Xie, H.; Steeves, R. M.; Lutz, R. J.; Zhao, R.; Wang, L.; Blattler, W. A.; Chari, R. V. Semisynthetic maytansine analogues for the targeted treatment of cancer J. Med. Chem. 2006, 49, 4392-4408 (Pubitemid 44036683)
10. Lambert, J. M. Antibody-maytansinoid conjugates: a new strategy for the treatment of cancer Drugs Future 2010, 35, 471-480
11. Damle, N. K. Tumour-targeted chemotherapy with immunoconjugates of calicheamicin Expert Opin. Biol. Ther. 2004, 4, 1445-1452 (Pubitemid 39222977)
12. Hamann, P. R.; Hinman, L. M.; Beyer, C. F.; Lindh, D.; Upeslacis, J.; Shochat, D.; Mountain, A. A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts Bioconjugate Chem. 2005, 16, 354-360 (Pubitemid 40388211)
13. Zhao, R. Y.; Sun, D.; Cavanagh, E.; Miller, M.; Leece, B.; Erickson, H.; Singh, R.; Kovtun, Y.; Goldmacher, V.; Chari, R. Design and Synthesis of PEG-Containing CC-1065 Analogs for Targeted Therapy of Cancer. Presented at the 233rd National Meeting of the American Chemical Society, Chicago, IL, U.S., 2006; No. 38, Medicinal Chemistry Section.
14. Chari, R. V.; Jackel, K. A.; Bourret, L. A.; Derr, S. M.; Tadayoni, B. M.; Mattocks, K. M.; Shah, S. A.; Liu, C.; Blattler, W. A.; Goldmacher, V. S. Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation Cancer Res. 1995, 55, 4079-4084
15. Alley, S. C.; Okeley, N. M.; Senter, P. D. Antibody-drug conjugates: targeted drug delivery for cancer Curr. Opin. Chem. Biol. 2010, 14, 529-537
16. Doronina, S. O.; Mendelsohn, B. A.; Bovee, T. D.; Cerveny, C. G.; Alley, S. C.; Meyer, D. L.; Oflazoglu, E.; Toki, B. E.; Sanderson, R. J.; Zabinski, R. F.; Wahl, A. F.; Senter, P. D. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity Bioconjugate Chem. 2006, 17, 114-124 (Pubitemid 43157592)
17. Hamann, P. R.; Hinman, L. M.; Beyer, C. F.; Greenberger, L. M.; Lin, C.; Lindh, D.; Menendez, A. T.; Wallace, R.; Durr, F. E.; Upeslacis, J. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance Bioconjugate Chem. 2005, 16, 346-353 (Pubitemid 40388210)
18. King, H. D.; Dubowchik, G. M.; Mastalerz, H.; Willner, D.; Hofstead, S. J.; Firestone, R. A.; Lasch, S. J.; Trail, P. A. Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains J. Med. Chem. 2002, 45, 4336-4343 (Pubitemid 35025579)
19. Alley, S. C.; Benjamin, D. R.; Jeffrey, S. C.; Okeley, N. M.; Meyer, D. L.; Sanderson, R. J.; Senter, P. D. Contribution of linker stability to the activities of anticancer immunoconjugates Bioconjugate Chem. 2008, 19, 759-765 (Pubitemid 351431408)
20. Blättler, W. A. K.; B., S.; Lambert, J. M.; Senter, P. D. New heterobifunctional protein cross-linking reagent that forms an acid labile link Biochemistry 1985, 24, 1517-1524
21. Lewis Phillips, G. D.; Li, G.; Dugger, D. L.; Crocker, L. M.; Parsons, K. L.; Mai, E.; Blattler, W. A.; Lambert, J. M.; Chari, R. V.; Lutz, R. J.; Wong, W. L.; Jacobson, F. S.; Koeppen, H.; Schwall, R. H.; Kenkare-Mitra, S. R.; Spencer, S. D.; Sliwkowski, M. X. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res. 2008, 68, 9280-9290
22. Erickson, H. K.; Park, P. U.; Widdison, W. C.; Kovtun, Y. V.; Garrett, L. M.; Hoffman, K.; Lutz, R. J.; Goldmacher, V. S.; Blattler, W. A. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing Cancer Res. 2006, 66, 4426-4433
23. Hollander, I.; Kunz, A.; Hamann, P. R. Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates Bioconjugate Chem. 2008, 19, 358-361 (Pubitemid 351213870)
24. Burke, P. J.; Senter, P. D.; Meyer, D. W.; Miyamoto, J. B.; Anderson, M.; Toki, B. E.; Manikumar, G.; Wani, M. C.; Kroll, D. J.; Jeffrey, S. C. Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues Bioconjugate Chem. 2009, 20, 1242-1250
25. King, H. D.; Yurgaitis, D.; Willner, D.; Firestone, R. A.; Yang, M. B.; Lasch, S. J.; Hellstrom, K. E.; Trail, P. A. Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: a novel method for increasing the potency of doxorubicin immunoconjugates Bioconjugate Chem. 1999, 10, 279-288 (Pubitemid 29147732)
26. Hamblett, K. J.; Senter, P. D.; Chace, D. F.; Sun, M. M.; Lenox, J.; Cerveny, C. G.; Kissler, K. M.; Bernhardt, S. X.; Kopcha, A. K.; Zabinski, R. F.; Meyer, D. L.; Francisco, J. A. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate Clin. Cancer Res. 2004, 10, 7063-7070 (Pubitemid 39383058)
27. Takeshita, A.; Shinjo, K.; Yamakage, N.; Ono, T.; Hirano, I.; Matsui, H.; Shigeno, K.; Nakamura, S.; Tobita, T.; Maekawa, M.; Ohnishi, K.; Sugimoto, Y.; Kiyoi, H.; Naoe, T.; Ohno, R. CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma Br. J. Haematol. 2009, 146, 34-43
28. Szakacs, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe, C.; Gottesman, M. M. Targeting multidrug resistance in cancer Nat. Rev. Drug Discovery 2006, 5, 219-234 (Pubitemid 43336035)
29. Gottesman, M. M. Mechanisms of cancer drug resistance Annu. Rev. Med. 2002, 53, 615-627 (Pubitemid 34177898)
30. Hall, M. D.; Handley, M. D.; Gottesman, M. M. Is resistance useless? Multidrug resistance and collateral sensitivity Trends Pharmacol. Sci. 2009, 30, 546-556
31. Saito, I.; Fukui, S. Studies on the oxidation products of lipoic acid J. Vitaminol. (Kyoto) 1967, 13, 115-121
32. Kluger, R.; Hunt, J. C. Carboxylic acid participation in amide hydrolysis. Competition between acid-catalyzed dehydration and anhydride formation J. Am. Chem. Soc. 1989, 111, 5921-5925
33. Garner, P.; Ho, W. B.; Grandhee, S. K.; Youngs, W. J.; Kennedy, V. O. Development of an asymmetric approach to the 3,8-diazabicyclo[3.2.1]octane moiety of quinocarcin via intramolecular 1,3-dipolar cycloadditions of photochemically generated azomethine ylides J. Org. Chem. 1991, 56, 5893-5903
34. Haval, K. P.; Mhaske, S. B.; Argade, N. P. Cyanuric chloride: decent dehydrating agent for an exclusive and efficient synthesis of kinetically controlled isomaleimides Tetrahedron 2006, 62, 937-942 (Pubitemid 41817102)
35. Lazar, A. C.; Wang, L.; Blattler, W. A.; Amphlett, G.; Lambert, J. M.; Zhang, W. Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry Rapid Commun. Mass Spectrom. 2005, 19, 1806-1814 (Pubitemid 40886704)
36. Sutherland, M. S.; Sanderson, R. J.; Gordon, K. A.; Andreyka, J.; Cerveny, C. G.; Yu, C.; Lewis, T. S.; Meyer, D. L.; Zabinski, R. F.; Doronina, S. O.; Senter, P. D.; Law, C. L.; Wahl, A. F. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates J. Biol. Chem. 2006, 281, 10540-10547 (Pubitemid 43864594)
37. Drake, W. V.; McElvain, S. M. The reaction of organic halides with piperidine. IV. Bromo esters J. Am. Chem. Soc. 1934, 56, 697-700
38. Awasthi, S.; Cheng, J.; Singhal, S. S.; Saini, M. K.; Pandya, U.; Pikula, S.; Bandorowicz-Pikula, J.; Singh, S. V.; Zimniak, P.; Awasthi, Y. C. Novel function of human RLIP76: ATP-dependent transport of glutathione conjugates and doxorubicin Biochemistry 2000, 39, 9327-9334 (Pubitemid 30626323)
39. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters Nat. Rev. Cancer 2002, 2, 48-58 (Pubitemid 37328807)
40. Gottesman, M. M.; Ambudkar, S. V. Overview: ABC transporters and human disease J. Bioenerg. Biomembr. 2001, 33, 453-458 (Pubitemid 34052570)
41. Raviv, Y.; Pollard, H. B.; Bruggemann, E. P.; Pastan, I.; Gottesman, M. M. Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells J. Biol. Chem. 1990, 265, 3975-3980
42. Kovtun, Y. V.; Audette, C. A.; Mayo, M. F.; Jones, G. E.; Doherty, H.; Maloney, E. K.; Erickson, H. K.; Sun, X.; Wilhelm, S.; Ab, O.; Lai, K. C.; Widdison, W. C.; Kellogg, B.; Johnson, H.; Pinkas, J.; Lutz, R. J.; Singh, R.; Goldmacher, V. S.; Chari, R. V. Antibody-maytansinoid conjugates designed to bypass multidrug resistance Cancer Res. 2010, 70, 2528-2537